v3.25.2
STOCK-BASED COMPENSATION
3 Months Ended 12 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]    
STOCK-BASED COMPENSATION

NOTE 11. STOCK-BASED COMPENSATION

As of March 31, 2025, the Company had an active stock-based incentive compensation plan and an employee stock purchase plan: the 2022 Equity Incentive Plan (the “2022 Plan”) and the 2022 Employee Stock Purchase Plan (the “ESPP”). All new equity compensation grants are issued under these two plans; however, outstanding awards previously issued under inactive plans will continue to vest and remain exercisable in accordance with the terms of the respective plans.

The 2022 Plan provides for the grant of stock and stock-based awards including stock options, restricted stock, restricted stock units, performance awards, and stock appreciation rights. As of March 31, 2025, there were approximately 174,000 shares available for grant under the 2022 Plan and approximately 43,000 shares available for grant under the ESPP.

Stock-Based Compensation Expense

Total stock-based compensation expense recognized in the Company’s condensed consolidated statements of operations is classified as follows:

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

Cost of revenue

 

$

105,734

 

 

$

125,632

 

Research and development

 

 

93,425

 

 

 

139,050

 

Selling and marketing

 

 

196,488

 

 

 

80,925

 

General and administrative

 

 

101,517

 

 

 

268,508

 

Total stock-based compensation expense

 

$

497,164

 

 

$

614,115

 

The Company’s stock-based compensation expense is based on the value of the portion of stock-based payment awards that are ultimately expected to vest. During the three months ended March 31, 2025 and 2024, stock-based compensation relating to stock-based awards granted to consultants was $219,316 and $69,800, respectively.

Restricted Stock Units

The Company grants Restricted Stock Units ("RSUs") to its employees for their services with a liquidity event requirement. The RSUs granted to employees vest over a period of time from the grant date and are subject to the participants continuing service to the Company over the period. The following table shows a summary of the Company's RSUs outstanding as of March 31, 2025 and December 31, 2024 as well as activity the year then ended:

 

 

RSUs

 

 

 

Number of Shares

 

 

Weighted Average Grant Date Fair Value

 

Unvested at December 31, 2024

 

 

4,562

 

 

$

223.07

 

RSUs vested (1)

 

 

(1,040

)

 

$

208.51

 

RSUs forfeited

 

 

(275

)

 

$

36.42

 

Unvested at March 31, 2025

 

 

3,247

 

 

$

243.54

 

(1)
Common stock underlying such vested RSUs was not yet formally issued by the Company.

The total grant date fair value of RSUs vested was $216,846 and $240,090 during the three months ended March 31, 2025 and 2024, respectively.

As of March 31, 2025, total unrecognized stock-based compensation costs related to RSUs were $787,329, which are expected to be recognized over a remaining weighted average period of 0.52 years. As of March 31, 2025, all of the outstanding RSUs are expected to vest.

Stock Options

The Company's outstanding stock options generally expire 10 years from the date of grant and are exercisable when the options vest, generally over four years, the majority of which vest at a rate of 25% on the first anniversary of the grant date, with the remainder vesting ratably each month over the next three years. A summary of stock option activity is as follows:

 

 

Number of Stock Options Outstanding

 

 

Weighted-Average Exercise Price

 

 

Weighted-Average Remaining Contractual Life (Years)

 

 

Aggregate Intrinsic Value

 

Options outstanding at December 31, 2024

 

 

218,430

 

 

$

40.80

 

 

 

7.1

 

 

$

7,375.15

 

Options cancelled or forfeited

 

 

(31,492

)

 

$

10.14

 

 

 

 

 

 

 

Options outstanding at March 31, 2025

 

 

186,938

 

 

$

45.96

 

 

 

4.0

 

 

$

 

Options exercisable at March 31, 2025

 

 

122,446

 

 

$

58.39

 

 

 

2.4

 

 

$

 

Options vested and expected to vest at March 31, 2025

 

 

186,938

 

 

$

45.96

 

 

 

4.0

 

 

$

 

The weighted-average grant date fair value of options granted to employees and consultants was nil and $0.17 per share for the three months ended March 31, 2025 and 2024, respectively.

As of March 31, 2025, total unrecognized stock-based compensation cost related to stock options was $570,832, which is expected to be recognized over a weighted-average period of 2.13 years.

The Company estimates the fair value of the options utilizing the Black-Scholes option pricing model, which is subjective and dependent upon several variables, including expected option term, expected volatility of the Company’s share price over the expected term, expected risk-free interest rate over the expected option term, and expected dividend yield rate over the expected option term, and actual forfeiture rates. A summary of the weighted-average assumptions the Company utilized for option grants during the three months ended March 31, 2025 and 2024, respectively, are as follows:

 

 

Three Months Ended March 31,

 

 

 

2025

 

2024

 

Expected term (in years)

 

N/A

 

 

4.0

 

Expected volatility

 

N/A

 

47.8%

 

Risk-free interest rate

 

N/A

 

4.0%

 

Expected dividend yield

 

N/A

 

0.0%

 

 

Common Stock Issued for Services

During the three months ended March 31, 2025, the Company entered into arrangements with non-employee consultants for services to be provided in exchange for the issuance of shares of the Company's common stock. As of March 31, 2025, the Company was required to but had not yet issued a total of 3,830,189 shares of common stock, (i) 1,000,000 of which were equity-classified, with 500,000 of those shares relating to services previously provided and the remaining 500,000 shares relating to services to be provided over the term of the agreements, and (ii) 2,830,189 of which were liability-classified.

Stock-based compensation expense for the equity-classified awards was recognized based on the fair value of the Company’s common stock on the date of grant over the requisite service period. For the three months ended March 31, 2025, a total of $136,384 of stock-based compensation expense was recognized for the equity classified awards. Additionally, $131,000 was recorded within prepaid expenses and other current assets for common stock issued for services not yet performed.

The liability-classified awards represented compensation for services to be provided over the term of the agreements and were measured based on a fixed monetary value to be paid to the non-employee consultants which will be settled by the issuance of a variable number of shares of common stock. As of and for three months ended March 31, 2025, the Company recorded stock-based compensation expense, along with a corresponding liability of $51,073, which is included in accrued expenses in the condensed consolidated balance sheet.

NOTE 11. STOCK-BASED COMPENSATION

As of December 31, 2024, the Company had an active stock-based incentive compensation plan and an employee stock purchase plan: the 2022 Equity Incentive Plan (the “2022 Plan”) and the 2022 Employee Stock Purchase Plan (the “ESPP”). All new equity compensation grants are issued under these two plans; however, outstanding awards previously issued under inactive plans will continue to vest and remain exercisable in accordance with the terms of the respective plans.

The 2022 Plan provides for the grant of stock and stock-based awards including stock options, restricted stock, restricted stock units, performance awards, and stock appreciation rights. As of December 31, 2024, there are 66,000 shares available for grant under the 2022 Plan and approximately 10,000 shares available for grant under the ESPP.

Stock-Based Compensation Expense

Total stock-based compensation expense recognized in the Company’s consolidated statements of operations is classified as follows:

 

 

Year ended December 31,

 

 

 

2024

 

 

2023

 

Cost of revenue

 

$

466,658

 

 

$

640,847

 

Research and development

 

 

476,666

 

 

 

617,386

 

Selling and marketing (1)

 

 

(181,160

)

 

 

266,675

 

General and administrative

 

 

1,103,931

 

 

 

965,501

 

Total stock-based compensation expense

 

$

1,866,095

 

 

$

2,490,409

 

_______________

(1)
Includes the reversal of stock compensation expense due to the departure of our Chief Marketing and Sales Officer in April 2024 and the resultant forfeiture of his unvested awards.

The Company’s stock-based compensation expense is based on the value of the portion of stock-based payment awards that are ultimately expected to vest. During the years ended December 31, 2024 and 2023, stock-based compensation relating to stock-based awards granted to consultants was $178,877 and $458,174, respectively.

Restricted Stock Units

The Company grants Restricted Stock Units ("RSUs") to its employees for their services with a liquidity event requirement. The RSUs granted to employees vest over a period of time from the grant date and are subject to the participants continuing service to the Company over the period. The following table shows a summary of the Company's RSUs outstanding as of December 31, 2024 as well as activity the year then ended:

 

 

RSUs

 

 

 

Number of Shares

 

 

Weighted Average Grant Date Fair Value

 

Unvested at December 31, 2023

 

 

22,213

 

 

$

208.80

 

RSUs granted

 

 

45,725

 

 

$

5.38

 

RSUs vested

 

 

(52,789

)

 

$

24.33

 

RSUs forfeited

 

 

(10,587

)

 

$

94.46

 

Unvested at December 31, 2024

 

 

4,562

 

 

$

223.07

 

The total grant date fair value of RSUs awarded was $246,000 and $1,709,217 for the years ended December 31, 2024 and 2023, respectively. The total grant date fair value of RSUs vested was $1,284,257 and $1,730,895 for the years ended December 31, 2024 and 2023, respectively.

As of December 31, 2024, total unrecognized stock-based compensation costs related to RSUs was $995,162, which is expected to be recognized over a remaining weighted average period of 0.84 years. As of December 31, 2024, all of the outstanding RSUs are expected to vest.

Stock Options

The Company's outstanding stock options generally expire 10 years from the date of grant and are exercisable when the options vest, generally over four years, the majority of which vest at a rate of 25% on the first anniversary of the grant date, with the remainder vesting ratably each month over the next three years. A summary of stock option activity is as follows:

 

 

Number of Stock Options Outstanding

 

 

Weighted-Average Exercise Price

 

 

Weighted-Average Remaining Contractual Life (Years)

 

 

Aggregate Intrinsic Value

 

Options outstanding at December 31, 2023

 

 

188,865

 

 

$

74.41

 

 

 

7.9

 

 

$

 

Options granted

 

 

64,564

 

 

$

2.77

 

 

 

 

 

 

 

Options exercised

 

 

 

 

$

 

 

 

 

 

 

 

Options cancelled or forfeited

 

 

(34,999

)

 

$

152.01

 

 

 

 

 

 

 

Options outstanding at December 31, 2024

 

 

218,430

 

 

$

40.80

 

 

 

7.1

 

 

$

7,375.15

 

Options exercisable at December 31, 2024

 

 

143,214

 

 

$

49.70

 

 

 

6.1

 

 

$

7,375.15

 

Options vested and expected to vest at December 31, 2024

 

 

218,430

 

 

$

40.80

 

 

 

7.0

 

 

$

7,375.15

 

The weighted-average grant date fair value of options granted to employees and consultants was $3.17 and $19.20 per share for the years ended December 31, 2024 and 2023, respectively.

Aggregate intrinsic value represents the difference between the estimated fair value of the underlying Common Stock and the exercise price of outstanding, in-the-money options. The aggregate intrinsic value of options exercised was nil and $1,040 for the years ended December 31, 2024 and 2023, respectively.

As of December 31, 2024, total unrecognized stock-based compensation cost related to stock options was $702,471, which is expected to be recognized over a weighted-average period of 2.21 years.

Determining the appropriate fair value of stock based awards requires the input of subjective assumptions including the fair value of the Company’s Common Stock, the expected life of the option, and expected stock price volatility. The Company used the Black Scholes option pricing model to value its stock option awards.

The Company estimates the fair value of the options utilizing the Black-Scholes option pricing model, which is dependent upon several variables, including expected option term, expected volatility of the Company’s share price over the expected term, expected risk-free interest rate over the expected option term, and expected dividend yield rate over the expected option term, and actual forfeiture rates. A summary of the assumptions the Company utilized for option grants during the years ended December 31, 2024 and 2023, respectively, are as follows:

 

 

Year ended December 31,

 

 

2024

 

2023

Expected term (in years)

 

4.0

 

0.75-5.0

Expected volatility

 

47.8% - 55.0%

 

44.9%-47.6%

Risk-free interest rate

 

4.0% - 4.5%

 

3.8%-5.5%

Expected dividend yield

 

0.0%

 

0.0%

 

Common Stock Issued for Services

During the year ended December 31, 2024, the Company paid for certain services through the issuance of 12,500 fully vested common stock. The common stock awards are equity-classified, and compensation expense was recognized based on the fair value of the Company's common stock on the date of issuance. Stock-based compensation expense associated with the awards was immaterial for the twelve months ended December 31, 2024.